Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tania Vashistha

Nephrology Mission Hills, CA Medical Doctor

NPI 1790080810 CMS profile 1069215

11165 Sepulveda Blvd, Mission Hills, CA 91345

Open in the dashboard

General payments

$1,869

67 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tania Vashistha of Mission Hills, CA is reported in the CMS Open Payments database as having received $1,869 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $352 16
2024 General $553 20
2023 General $392 9
2022 General $427 16
2021 General $114 5
2019 General $30 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tania Vashistha
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Tania Vashistha were reported at $352. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Tania Vashistha Nephrology median Middle half National median
2019 $30 $236 $90–$588 $163
2020 $0 $135 $46–$364 $114
2021 $114 $202 $67–$551 $132
2022 $427 $242 $77–$695 $149
2023 $392 $254 $84–$766 $160
2024 $553 $300 $99–$852 $164
2025 $352 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $633 15 payments
  2. Relypsa, Inc. $227 10 payments
  3. Otsuka America Pharmaceutical, Inc. $183 8 payments
  4. Amgen Inc. $147 6 payments
  5. Novartis Pharmaceuticals Corporation $137 2 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $136 7 payments
  7. Calliditas Therapeutics US Inc. $91 4 payments
  8. Fresenius USA Marketing, Inc. $68 3 payments
  9. Akebia Therapeutics Inc $54 2 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $43 2 payments
  11. Other $148 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,823 64 payments
  2. Education $45 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $562 12 payments
  2. Veltassa $188 8 payments
  3. JYNARQUE $183 8 payments
  4. Kerendia $136 7 payments
  5. LOKELMA $129 4 payments
  6. TAVNEOS $84 4 payments
  7. Velphoro $68 3 payments
  8. TARPEYO $55 2 payments
  9. Vafseo $54 2 payments
  10. JARDIANCE $43 2 payments
  11. Other $340 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

1,914

Median for Nephrology: 954

Drug cost

$632,302

Median for Nephrology: $127,050

Branded share of claims

22.5%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jynarque Tolvaptan Brand 13 $251,027
Veltassa Patiromer Calcium Sorbitex Brand 81 $106,358
Farxiga Dapagliflozin Propanediol Brand 72 $73,765
Lokelma Sodium Zirconium Cyclosilicate Brand 73 $71,270
Velphoro Sucroferric Oxyhydroxide Brand 13 $28,865
Procrit Epoetin Alfa Brand 19 $19,760
Lanthanum Carbonate Generic 16 $17,909
Jardiance Empagliflozin Brand 11 $12,529
Retacrit Epoetin Alfa-Epbx Brand 22 $11,533
Cinacalcet Hcl Generic 41 $8,033

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$93,774

Medicare's payments for the services billed

Medicare patients

179

Average age 74

Services billed

1,159

82 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 71%
Heart failure 50%
Ischemic heart disease 47%
Arthritis 44%
Atrial fibrillation 34%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOKELMA
  • AstraZeneca Pharmaceuticals LP $100
$100 73 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $94
$94 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $92
$92 72 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $43
$43 11 —
IBSRELA
  • Ardelyx, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record